Real-world analysis links Zepbound to lower healthcare costs in adults over 55 with obesity, Eli Lilly says

Eli Lilly said a real-world study of adults over age 55 with overweight or obesity found that staying on Zepbound (tirzepatide) for weight management was associated with lower healthcare costs. The company framed the analysis as evidence that sustained treatment may reduce downstream spending, rather than just improving weight-related metrics.

The study focused on adults 55 and older, a demographic where weight and related chronic conditions can drive higher medical utilization. According to Lilly’s announcement, participants were followed in routine care settings, and outcomes were compared based on whether patients remained on Zepbound versus stopping treatment.

Lilly did not provide, in the material available for this report, a full description of the study design, including how patients were selected, how long patients were observed, or whether adjustments were made for differences in baseline health status. The company also did not disclose the size of the cost differences in the excerpt provided here, nor did it specify what types of healthcare spending were included in the totals.

The company’s emphasis was on the relationship between continued use and lower costs, which is a common policy and payer concern in obesity pharmacotherapy. In practical terms, cost outcomes can reflect fewer visits, fewer treatments for obesity-related complications, or lower overall utilization among people who remain on therapy, but the disclosed information did not confirm which of those mechanisms drove the result.

Lilly has positioned Zepbound as a treatment for weight management and has previously argued that GLP-1 and related medicines can help address obesity’s broader health impacts. Real-world analyses like this are often used to test whether benefits seen in clinical trials translate into everyday settings, where adherence, dosing patterns, and care decisions can differ.

Even with that context, the evidence in the announcement is necessarily limited in what it reveals publicly. Without details on the methodology, it is not possible to determine how much of the cost reduction could be attributed to Zepbound itself versus differences in patient behavior or healthcare access between those who stayed on the drug and those who discontinued.

What to watch next is whether Lilly will publish more complete data, such as study duration, treatment persistence definitions, patient demographics, and a breakdown of which cost categories changed. Those specifics would help clinicians, payers, and researchers evaluate the robustness of the findings and compare them with other real-world evidence emerging in the obesity medicine market.